Toward optimizing the use of deferasirox: Potential benefits of combined use with deferoxamine

Haematologica

Volumn 98, Issue 1, 2013, Pages 129-135

  Grady, Robert W ^a   Galanello, Renzo ^b   Randolph, Rachel E ^a   Kleinert, Dorothy A ^a   Dessi, Carlo ^b   Giardina, Patricia J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON;

ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON INTAKE; IRON METABOLISM; MALE; TOXICITY;

ADULT; BENZOATES; BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; TRIAZOLES;

EID: 84872075974     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.070607     Document Type: Article

References (55)

1. Wonke B. Clinical management of betathalassemia major. Semin Hematol. 2001; 38(4):350-9.
2. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-88.
3. Graziano JH, Grady RW, Cerami A. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron-chelating drug. J Pharmacol Exp Ther. 1974;190(3):570-5.
4. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann NY Acad Sci. 2010;1202:1-9.
5. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med. 1989;7(6):645-51.
6. Perera NJ, Lau NS, Mathews S, Waite C, Ho PJ, Caterson ID. Overview of endocrinopathies associated with b-thalassaemia major. Intern Med J. 2010;40(10): 689-96.
7. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
8. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96.
9. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777-8.
10. Modell B, Khan M, Darlison M. Survival in b-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet. 2000;355(9220):2051-2.
11. Giardina PJ, Grady RW. Chelation therapy in b-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol. 1995;32(4):304-12.
12. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-52.
13. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42(2 Suppl 1):S19-21.
14. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active iron chelator for treatment of iron overload. Lancet. 1987;1(8545):1294-5.
15. Grady RW, Hershko C. An evaluation of the potential of HBED as an orally-effective iron-chelating drug. Semin Hematol. 1990;27(2):105-11.
16. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S. Design of orally active iron chelators. Acta Haematol. 1996;95(1):6-12.
17. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918-22.
18. Taher AT, Sheikh-Taha M, Sharara A, Inati A, Koussa S, Ellis G, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a twoyear study. Acta Haematol. 2005;114(3): 146-9.
19. Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: its efficacy relative to that of desferal. Blood. 1996; 88:310a.
20. Kidson-Gerber G, Lindeman R. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassemia major patients: does the addition of deferiprone improve adherence? Br J Haematol. 2008;142(4):668-80.
21. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta thalassemia. Lancet. 2002;360(9332): 516-20.
22. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a largescale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330-6.
23. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of longterm therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-7.
24. Grady RW, Berdoukas VA, Giardina PJ. Iron chelation: combined therapy could be a better approach. Blood. 1998;92:16b.
25. Grady RW, Giardina PJ. Iron Chelators: New Development Strategies. Ponte Vedra Beach: DG Badman, RJ Bergeron and GM Brittenham; c2000. Chapter, Iron chelation: the rationale for combination therapy; p. 293-310.
26. Grady RW, Berdoukas V, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. Blood. 2002; 100:241a. Abstract.
27. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241-3.
28. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115(14):1876-84.
29. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599-606.
30. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008; 10(1):12.
31. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalization of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassemia major. Br J Haematol. 2009;148(3):466-75.
32. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145(2):245-54.
33. Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45(2):136-9.
34. Galanello R, Piga A, Alberti D, Rouan M-C, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670: a new orally active iron chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43(6):565-72.
35. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91(7):873-80.
36. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-62.
37. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with betathalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458-65.
38. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' followup. Blood. 2011;118(4):884-93.
39. Pennell DJ, Porter JB, Cappellini MD, ElBashlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in b-thalassemia. Blood. 2010;115(12):2364-71.
40. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011; 96(1):41-7.
41. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-41.
42. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009.114(19):4009-13.
43. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, et al. Effectiveness and safety of ICL670 in ironloaded patients with thalassemia: a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361 (9369):1597-602.
44. Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008; 48(4):428-35.
45. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-7.
46. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, et al. Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with b-thalassaemia. Eur J Haematol. 2011;87(4):355-65.
47. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9(4):633-41.
48. Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent b-thalassemia. Pediatr Blood Cancer. 2011;56(3):420-4.
49. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86(5):433-6.
50. Weiss HM, Fresneau M, Camenisch GP, Kretz O, Gross G. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos. 2006;34(6):971-5.
51. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res. 2010;156(2):55-67.
52. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88(2):705-13.
53. Daar S, Ahmed S, Berdoukas V. Rapid iron loading in heart and liver in a patient with transfusion dependent thalassaemia after brief poor compliance with iron chelation therapy. Sultan Qaboos Univ Med J. 2010; 10(3):401-4.
54. Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, et al. Combining two orally active iron chelators for thalassemia. Ann Hematol. 2010;89(11):1177-8.
55. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after singleagent chelation therapies. Br J Haematol. 2011;154(5):654-6